Commentary|Articles|November 17, 2026

Supplements and Featured Publications

  • Outlining Research Advancements and Future Directions in Uveal Melanoma
  • Volume 1
  • Issue 1

TCR-Based Strategies and Tolerable Combinations Begin to Narrow the Outcome Gap in Uveal Melanoma

Fact checked by: Ashling Wahner
Listen
0:00 / 0:00

Ryan J. Sullivan, MD, discusses HLA testing, liver-directed therapy, and emerging targeted and T-cell–based therapies for metastatic uveal melanoma.

Treatments built around the biology of uveal melanoma, from targeted agents to T-cell receptor (TCR)–based therapies, are beginning to change treatment outcomes for patients with metastatic disease, and patients with HLA-A*02:01–negative disease may soon have a targeted therapy option, according to Ryan J. Sullivan, MD.

The FDA approved tebentafusp-tebn (Kimmtrak) in January 2022 for the treatment of adult patients with HLA-A*02:01–positive unresectable or metastatic uveal melanoma; however, patients in the HLA-A*02:01–negative population are ineligible for the agent.1 In that population, first-line darovasertib (DE196; LXS196), an oral protein kinase C inhibitor, plus the MET inhibitor crizotinib (Xalkori; n = 210) produced a median progression-free survival by blinded independent central review of 6.9 months (95% CI, 5.6-8.3) vs 3.1 months (95% CI, 1.8-4.2) with investigator’s choice of immunotherapy (n = 103; HR, 0.42; 95% CI, 0.30-0.59; P < .0001) in the phase 2/3 OptimUM-02 trial (NCT05987332), findings from which were presented at the 2026 ASCO Annual Meeting.2 The objective response rates (ORRs) were 37.1% (95% CI, 30.6%-44.1%) vs 5.8% (95% CI, 2.2%-12.3%), respectively (OR, 10.8; 95% CI, 4.4-26.4; P < .0001).

In HLA-A*02:01–positive patients, brenetafusp (IMC-F106C), a PRAME-directed TCR bispecific antibody, plus tebentafusp produced an ORR of 29%, a median duration of response of 24.1 months, and a median progression-free survival of 8.1 months (95% CI, 1.9-30.4) among 17 evaluable patients treated in the first-line setting in a phase 1/2 trial (NCT04262466), according to data presented at the 2026 SITC Annual Meeting (SITC 2026).3 The estimated 2-year overall survival rate was 70%.

“When you pair [these new therapies] with some of the developments with liver-directed therapy, we can now anticipate that patients can live a long time, much longer than a few months, which was the previous prognosis for patients with metastatic uveal melanoma,” Sullivan said in an exclusive interview with OncLive®.

In the interview, Sullivan discussed how uveal melanoma differs biologically from cutaneous melanoma, the role of HLA status in treatment selection, how tebentafusp is combined with liver-directed therapy, and the investigational approaches he finds most promising.

Sullivan is an associate professor of medicine at Harvard Medical School and a medical oncologist at Massachusetts General Hospital in Boston, Massachusetts.

OncLive: How does uveal melanoma differ from cutaneous melanoma in its biology and presentation?

Sullivan: All melanomas start in pigmented cells called melanocytes. Most of these are on our skin, but we also have them in our eyes and on the lining surfaces of the body. Where the melanoma arises matters. Melanoma on the skin is often related to ultraviolet (UV) exposure, and at the DNA level, you can see a signature of UV damage. Uveal melanomas are not typically related to sun exposure; they arise in structures where the sun doesn’t shine.

That has biologically relevant consequences. Immunotherapy, which is the standard of care for all melanomas, is generally more effective in tumors that arise from UV damage, because there are many more changes in the DNA that our immune system can recognize. Patients with eye melanoma [have less favorable outcomes] with immunotherapy, and one of the major reasons is that their tumors don’t have the same degree of damage at the DNA level.

The driver genes are also different. Approximately half of skin melanomas have an alteration in BRAF, and about a quarter have an alteration in NRAS. Those alterations aren’t seen in uveal melanoma, which is driven by changes in G protein–coupled receptors or the molecules that signal from them, most commonly GNAQ and GNA11. These are rarer drivers, so [drug development in uveal melanoma] can’t take advantage of developments in other cancers as much.

Detection differs, too. Patients can monitor a changing skin lesion themselves. For eye melanoma, unless the tumor [affects vision] or causes pain, we often won’t pick it up until [the patient] has an eye exam.

HLA Status and Emerging Therapies in Uveal Melanoma: Key Highlights

  • Uveal melanoma lacks the UV-related DNA damage and BRAF or NRAS alterations seen in skin melanoma, which helps explain why immunotherapy is less effective in this disease.
  • HLA-A*02:01 status, present in about 40% to 50% of patients of European descent, determines eligibility for tebentafusp, and treating 1 or 2 progressing lesions with liver-directed or other local therapy can extend its benefit.
  • Darovasertib plus crizotinib for HLA-A*02:01–negative disease, PRAME-directed TCR T-cell therapy, and brenetafusp plus tebentafusp are emerging options designed specifically for uveal melanoma.

How does HLA status inform treatment decisions in uveal melanoma?

HLA-A status is important because some therapies only work if [the patient has] the matched HLA type. One of those therapies is tebentafusp, a bispecific molecule. One end looks like a TCR, which is how our immune system recognizes small pieces of protein presented on the surface of cells, including cancer cells. That recognition only works when the HLA is matched. Our immune system is matched to our HLA, and a tumor cell comes from us, so it has the same HLA status. Tebentafusp’s TCR recognizes a small piece of a protein called gp100, and it’s tagged to a T-cell engager, so it brings the tumor cell and the T cell together, and the T cell can kill the tumor cell.

If a patient doesn’t have matched HLA, specifically HLA-A*02:01, tebentafusp is never going to work. Among people of European descent, approximately 40% to 50% have inherited HLA-A*02:01. Therefore, although [tebentafusp is] not an option for most of our patients, it’s an option for many of them. There are also emerging engineered T-cell products that require [a specific] HLA type.

How is tebentafusp integrated with liver-directed and other local therapies?

Most patients with uveal melanoma have [disease that has] spread to the liver, and that’s often why patients die from this disease: the liver gets so full of tumor that it stops working. It’s less clear why uveal melanoma spreads there, because blood flow from the eye does not go directly to the liver. It probably has more to do with the molecular alterations in these tumors and the signals they drive. Because of other diseases, including hepatocellular carcinoma, there are many strategies to treat tumors in the liver: radiation, ablation, and delivery of chemotherapy or radiotherapeutics through the liver’s blood supply.

When tebentafusp was approved, we didn’t know how well it would work with local therapies. As we rolled it out, sometimes just 1 or 2 [melanoma] spots were growing [in a patient], so we radiated them or delivered liver-directed therapy, or local therapy if the growing tumor was in the bone, lung, or elsewhere. We found that this extended the benefit of tebentafusp substantially. Tebentafusp may work for 6 or 8 months, and then 1 or 2 areas progress; you deal with those and continue treatment for another 6, 8, or 10 months, potentially longer.

Which investigational approaches in uveal melanoma are most promising?

There are 3 with data from this past year. The first is a combination of 2 pills, darovasertib and crizotinib. Darovasertib blocks protein kinase C, which is directly in the signaling cascade of tumors with GNAQ or GNA11 mutations, but by itself, it doesn’t seem to work all that well. Signaling through hepatocyte growth factor and its receptor, MET, also plays a role, and combining darovasertib with crizotinib, which was developed as a MET inhibitor, seemed to work better, particularly in patients who hadn’t been heavily pretreated. In the [OptimUM-02] trial, patients were less likely to progress at any time point with darovasertib plus crizotinib than with investigator’s choice of therapy.2 Hopefully, that will become part of the standard of care [SOC] in the coming year or so.

The second is anzutresgene autoleucel [IMA203], a cell therapy in which T cells are engineered with a TCR that recognizes PRAME. Patients receive chemotherapy to prepare the body, and then they receive the cells. Data presented [in 2025 and 2026, such as those from the phase 1b SUPRAME trial (NCT06743126) of the agent in patients with advanced melanoma] suggest that upwards of half of patients with uveal melanoma may have regression of their disease with this [therapy].4

The third is tebentafusp plus brenetafusp. Brenetafusp is the same kind of molecule as tebentafusp, a TCR combined with a T-cell engager, but it binds a small piece of PRAME instead of gp100. The combination seemed to be associated with higher response rates and, more importantly, a longer time to progression than either agent alone, and the survival outcomes were good [in a phase 1/2 trial].3 [This trial] only [evaluated 17] patients, which isn’t enough to support an approval, but a study to further investigate the combination was announced [at SITC 2026].

What is known about the safety profile of brenetafusp plus tebentafusp?

Giving both drugs at the same time initially caused more cytokine release syndrome. However, if you give one [agent] for a few weeks first and then add the other, [the regimen] seems to be fairly safe. Once patients tolerate tebentafusp, brenetafusp, or the combination, there doesn’t seem to be cumulative toxicity; most of the toxicity is [seen] early. [These agents] can control tumor growth for a long time.

What is the key message for community oncologists treating patients with uveal melanoma?

This is a disease that is hard to manage. The drugs developed over the past decade and a half for [cutaneous] melanoma don’t work as well in uveal melanoma, but they’re still our SOC for patients who are HLA-A*02:01 negative, because tebentafusp is only approved for patients who are HLA-A*02:01 positive. We’re perhaps not quite there yet to say we have therapies that have closed the gap in outcomes between skin and uveal melanoma, but we’re getting there.

If you’re a community oncologist without access to the newer drugs, referral centers that see many of these patients have access to them. Reaching out to a center of excellence may be the best way to get your patients those drugs.

References

  1. Immunocore announces FDA approval of Kimmtrak (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma. News release. Immunocore. January 26, 2022. Accessed November 17, 2026. https://www.immunocore.com/investors/news/press-releases/detail/46/immunocore-announces-fda-approval-of-kimmtrak-tebentafusp-tebn-for-the-treatment-of-unresectable-or-metastatic-uveal-melanoma
  2. Orloff MM, Ramelyte E, Butler MO, et al. Darovasertib plus crizotinib vs investigator’s choice as first-line treatment for patients with HLA-A2 negative metastatic uveal melanoma: primary results from the OptimUM-02 trial. J Clin Oncol. 2026;44(suppl 17):LBA9503. doi:10.1200/JCO.2026.44.17_suppl.LBA9503
  3. Shoushtari AN, Orloff M, AR Naqash, et al. Phase 1 evaluation of brenetafusp alone and in combination with tebentafusp in metastatic uveal melanoma. Presented at: 2026 Society for Immunotherapy of Cancer Annual Meeting; November 4-8, 2026; Phoenix, AZ. Abstract 1187.
  4. Davar D, Patel SP, Hernandez-Aya LF, et al. Patient-level clinical response dynamics in advanced melanoma with anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-cell therapy. J Clin Oncol. 2026;44(suppl 16):9508. doi:10.1200/JCO.2026.44.16_suppl.9508

Related to this article